新生儿持续性肺动脉高压病理生理机制及治疗的研究进展  

Pathophysiological Mechanism and Treatment of Persistent Pulmonary Hypertension of the Newborn

作　　者：禚月 鲍霞[1] 庄贺[1] 石金虎 ZHUO Yue;BAO Xia;ZHUANG He;SHI Jinhu(Faculty of Rehabilitation Medicine,Shandong University of Traditional Chinese Medicine,Jinan 250355,Shandong,China;Department of Cardiology,The Second Hospital of Shandong University,Jinan 250033,Shandong,China)

机构地区：[1]山东中医药大学康复医学院,山东济南250355 [2]山东大学第二医院心血管内科,山东济南250033

出　　处：《心血管病学进展》2024年第12期1094-1098,共5页Advances in Cardiovascular Diseases

基　　金：山东省中医药科技项目(2021Q081);山东省教育厅研究生教育教学改革研究项目(SDYJSJGC2023021)。

摘　　要：新生儿持续性肺动脉高压是导致新生儿死亡的重要原因之一,是一类恶性进行性肺血管疾病,病情持续进展引发患儿呼吸受限、低氧血症,最终导致右心衰竭严重威胁患儿的生命。而存活的患儿也常留有其他系统的后遗症,长期影响其生活质量。现就新生儿持续性肺动脉高压的病理生理机制及治疗进展展开综述,以期为相关研究及临床诊断和治疗提供参考。Persistent pulmonary hypertension of the newborn is one of the important causes of death in newborn infants,and it is a type of malignant progressive pulmonary vascular disease.The condition leads to respiratory restriction,hypoxemia,and eventually right heart failure,which seriously threatens the lives of children.Surviving children often have sequelae of other systems,which have a long-term impact on their quality of life.This article reviews the pathophysiological mechanism and treatment progress of neonatal persistent pulmonary hypertension,in order to provide reference for related research,clinical diagnosis and treatment.

关 键 词：新生儿持续性肺动脉高压 病理生理机制 药物治疗 吸入性一氧化氮 

分 类 号：R722.1[医药卫生—儿科]